Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?

Lynn A. Fussner, Ulrich Specks

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose of review The role of serial antineutrophil cytoplasmic antibody (ANCA) measurements to guide immunosuppressive therapy in pauci-immune vasculitis is an area of ongoing controversy. Evidence elucidating the relationship between ANCA levels and disease activity continues to grow. Recent findings The finding that proteinase 3-ANCA and myeloperoxidase-ANCA-associated diseases differ genetically has challenged the traditional classification and study of pauci-immune vasculitis. Multiple studies have also found that the clinical features and course of disease differ by ANCA antigen specificity more than clinical diagnosis. Advances in diagnostic assays and new techniques for the evaluation of ANCA levels over time have yielded improved assay performance in specific subsets of patients. In addition, increasing use of rituximab has added to our understanding of the relationship of ANCA levels to B-cell counts and disease relapse, which may differ by treatment regimen. Summary The relationship between ANCA levels and disease activity is impacted by multiple factors, including antigen specificity, disease manifestations, clinical assay, and therapeutic regimen. Each of these must be taken into account when determining the significance of ANCA levels during long-term follow-up of pauci-immune vasculitis.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalCurrent Opinion in Rheumatology
Volume27
Issue number3
DOIs
StatePublished - May 7 2015

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antineutrophil Cytoplasmic Antibodies
Therapeutics
Myeloblastin
Antigens
Antibody Specificity
Immunosuppressive Agents
Peroxidase
B-Lymphocytes
Cell Count

Keywords

  • Capillaritis
  • Glomerulonephritis
  • Myeloperoxidase-antineutrophil cytoplasmic antibody
  • Proteinase 3-antineutrophil cytoplasmic antibody
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis? / Fussner, Lynn A.; Specks, Ulrich.

In: Current Opinion in Rheumatology, Vol. 27, No. 3, 07.05.2015, p. 231-240.

Research output: Contribution to journalArticle

@article{da58da84d0664983b18e6c97b7795ac9,
title = "Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?",
abstract = "Purpose of review The role of serial antineutrophil cytoplasmic antibody (ANCA) measurements to guide immunosuppressive therapy in pauci-immune vasculitis is an area of ongoing controversy. Evidence elucidating the relationship between ANCA levels and disease activity continues to grow. Recent findings The finding that proteinase 3-ANCA and myeloperoxidase-ANCA-associated diseases differ genetically has challenged the traditional classification and study of pauci-immune vasculitis. Multiple studies have also found that the clinical features and course of disease differ by ANCA antigen specificity more than clinical diagnosis. Advances in diagnostic assays and new techniques for the evaluation of ANCA levels over time have yielded improved assay performance in specific subsets of patients. In addition, increasing use of rituximab has added to our understanding of the relationship of ANCA levels to B-cell counts and disease relapse, which may differ by treatment regimen. Summary The relationship between ANCA levels and disease activity is impacted by multiple factors, including antigen specificity, disease manifestations, clinical assay, and therapeutic regimen. Each of these must be taken into account when determining the significance of ANCA levels during long-term follow-up of pauci-immune vasculitis.",
keywords = "Capillaritis, Glomerulonephritis, Myeloperoxidase-antineutrophil cytoplasmic antibody, Proteinase 3-antineutrophil cytoplasmic antibody, Rituximab",
author = "Fussner, {Lynn A.} and Ulrich Specks",
year = "2015",
month = "5",
day = "7",
doi = "10.1097/BOR.0000000000000170",
language = "English (US)",
volume = "27",
pages = "231--240",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?

AU - Fussner, Lynn A.

AU - Specks, Ulrich

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Purpose of review The role of serial antineutrophil cytoplasmic antibody (ANCA) measurements to guide immunosuppressive therapy in pauci-immune vasculitis is an area of ongoing controversy. Evidence elucidating the relationship between ANCA levels and disease activity continues to grow. Recent findings The finding that proteinase 3-ANCA and myeloperoxidase-ANCA-associated diseases differ genetically has challenged the traditional classification and study of pauci-immune vasculitis. Multiple studies have also found that the clinical features and course of disease differ by ANCA antigen specificity more than clinical diagnosis. Advances in diagnostic assays and new techniques for the evaluation of ANCA levels over time have yielded improved assay performance in specific subsets of patients. In addition, increasing use of rituximab has added to our understanding of the relationship of ANCA levels to B-cell counts and disease relapse, which may differ by treatment regimen. Summary The relationship between ANCA levels and disease activity is impacted by multiple factors, including antigen specificity, disease manifestations, clinical assay, and therapeutic regimen. Each of these must be taken into account when determining the significance of ANCA levels during long-term follow-up of pauci-immune vasculitis.

AB - Purpose of review The role of serial antineutrophil cytoplasmic antibody (ANCA) measurements to guide immunosuppressive therapy in pauci-immune vasculitis is an area of ongoing controversy. Evidence elucidating the relationship between ANCA levels and disease activity continues to grow. Recent findings The finding that proteinase 3-ANCA and myeloperoxidase-ANCA-associated diseases differ genetically has challenged the traditional classification and study of pauci-immune vasculitis. Multiple studies have also found that the clinical features and course of disease differ by ANCA antigen specificity more than clinical diagnosis. Advances in diagnostic assays and new techniques for the evaluation of ANCA levels over time have yielded improved assay performance in specific subsets of patients. In addition, increasing use of rituximab has added to our understanding of the relationship of ANCA levels to B-cell counts and disease relapse, which may differ by treatment regimen. Summary The relationship between ANCA levels and disease activity is impacted by multiple factors, including antigen specificity, disease manifestations, clinical assay, and therapeutic regimen. Each of these must be taken into account when determining the significance of ANCA levels during long-term follow-up of pauci-immune vasculitis.

KW - Capillaritis

KW - Glomerulonephritis

KW - Myeloperoxidase-antineutrophil cytoplasmic antibody

KW - Proteinase 3-antineutrophil cytoplasmic antibody

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84926375231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926375231&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000170

DO - 10.1097/BOR.0000000000000170

M3 - Article

C2 - 25775187

AN - SCOPUS:84926375231

VL - 27

SP - 231

EP - 240

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -